MA54501A - Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer - Google Patents

Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer

Info

Publication number
MA54501A
MA54501A MA054501A MA54501A MA54501A MA 54501 A MA54501 A MA 54501A MA 054501 A MA054501 A MA 054501A MA 54501 A MA54501 A MA 54501A MA 54501 A MA54501 A MA 54501A
Authority
MA
Morocco
Prior art keywords
treatment
specific binding
binding proteins
cancer diagnosis
folr1
Prior art date
Application number
MA054501A
Other languages
English (en)
Inventor
Eva Bosse-Doenecke
Erik Fiedler
Manja Gloser
Ulrich Haupts
Original Assignee
Navigo Proteins Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navigo Proteins Gmbh filed Critical Navigo Proteins Gmbh
Publication of MA54501A publication Critical patent/MA54501A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA054501A 2018-12-18 2019-12-17 Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer MA54501A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213661 2018-12-18
EP19160572 2019-03-04

Publications (1)

Publication Number Publication Date
MA54501A true MA54501A (fr) 2021-10-27

Family

ID=68848307

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054501A MA54501A (fr) 2018-12-18 2019-12-17 Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer

Country Status (14)

Country Link
US (1) US20220127312A1 (fr)
EP (1) EP3898659A1 (fr)
JP (2) JP2022514860A (fr)
KR (1) KR20210104106A (fr)
CN (1) CN113166217A (fr)
AU (1) AU2019409572B2 (fr)
BR (1) BR112021009912A2 (fr)
CA (1) CA3123986A1 (fr)
IL (1) IL284097A (fr)
MA (1) MA54501A (fr)
MX (1) MX2021007283A (fr)
PH (1) PH12021551174A1 (fr)
SG (1) SG11202105029WA (fr)
WO (1) WO2020127224A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
WO2022098743A1 (fr) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imagerie et procédés thérapeutiques ciblant le récepteur 1 de folate (folr1)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
US8748351B2 (en) * 2009-12-14 2014-06-10 Scil Proteins Gmbh Method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
CA2975362A1 (fr) * 2015-02-06 2016-08-11 Navigo Proteins Gmbh Proteines de liaison du recepteur du facteur de croissance epidermique (egfr) comprenant des muteines d'ubiquitine
JP6881760B2 (ja) * 2015-07-20 2021-06-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質に基づくＨｅｒ２結合タンパク質
JP2018520675A (ja) * 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CN107793471B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽4及其应用

Also Published As

Publication number Publication date
PH12021551174A1 (en) 2021-10-25
WO2020127224A1 (fr) 2020-06-25
JP2022514860A (ja) 2022-02-16
SG11202105029WA (en) 2021-06-29
US20220127312A1 (en) 2022-04-28
AU2019409572B2 (en) 2022-11-24
BR112021009912A2 (pt) 2022-01-18
CN113166217A (zh) 2021-07-23
EP3898659A1 (fr) 2021-10-27
KR20210104106A (ko) 2021-08-24
CA3123986A1 (fr) 2020-06-25
JP2023157023A (ja) 2023-10-25
MX2021007283A (es) 2021-07-15
IL284097A (en) 2021-08-31
AU2019409572A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA44670A (fr) Protéines de liaison trispécifiques et/ou trivalentes
AR103675A1 (es) Anticuerpos anti-ctla4 terapéuticos
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
WO2017081211A3 (fr) Polypeptides de liaison d'antigène dirigés contre cd38
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA49368A (fr) Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA54501A (fr) Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
MA51741A (fr) Procédés thérapeutiques et de diagnostic pour des maladies inflammatoires médiées par des mastocytes
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA44378A (fr) Protéines de fusion immunogènes pour le traitement du cancer
MA53252A (fr) Thérapie génique non perturbatrice pour le traitement d'un mma
MA52627A (fr) Traitement du cancer